| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 402.818 | 1.094.621 | 1.686.866 | 1.774.100 | 2.325.291 |
| Total Income - EUR | - | - | - | - | - | 402.862 | 1.094.727 | 1.691.085 | 1.794.717 | 2.332.072 |
| Total Expenses - EUR | - | - | - | - | - | 379.108 | 1.047.655 | 1.568.009 | 1.783.895 | 2.147.166 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 23.755 | 47.072 | 123.076 | 10.822 | 184.906 |
| Net Profit/Loss - EUR | - | - | - | - | - | 19.726 | 39.791 | 107.228 | 3.755 | 144.308 |
| Employees | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Nutrapharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 50.952 | 35.410 | 21.064 | 6.621 | 74.059 |
| Current Assets | - | - | - | - | - | 746.955 | 828.143 | 1.164.534 | 1.401.236 | 2.081.340 |
| Inventories | - | - | - | - | - | 0 | 0 | 24.778 | 208.889 | 383.297 |
| Receivables | - | - | - | - | - | 746.088 | 719.074 | 1.135.070 | 1.181.359 | 1.591.602 |
| Cash | - | - | - | - | - | 867 | 109.069 | 4.686 | 10.988 | 106.441 |
| Shareholders Funds | - | - | - | - | - | 19.768 | 52.737 | 147.791 | 92.076 | 190.016 |
| Social Capital | - | - | - | - | - | 41 | 40 | 40.556 | 40.433 | 40.207 |
| Debts | - | - | - | - | - | 778.139 | 810.816 | 1.037.930 | 1.333.329 | 1.976.411 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4639 - 4639" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Nutrapharm S.r.l.